FDA Warns Medtronic Over Heart Rhythm Unit

By Erin Marie Daly

Law360, New York (November 18, 2009, 4:02 PM ET) -- Medtronic Inc. announced Wednesday that it had received a warning letter from the U.S. Food and Drug Administration regarding an inspection of its heart rhythm device facility over problems the agency found at the unit’s corporate headquarters.

Minneapolis-based Medtronic said the letter related to an August probe conducted at the company’s Cardiac Rhythm Disease Management business, which is based in Mounds View, Minn.

According to Medtronic, the FDA’s observations fall into four general categories: corrective and preventive action and field action timeliness; review and documentation of...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles